Annual Accounts Payable
$9.85 M
-$3.13 M-24.13%
31 December 2023
Summary:
Nektar Therapeutics annual accounts payable is currently $9.85 million, with the most recent change of -$3.13 million (-24.13%) on 31 December 2023. During the last 3 years, it has fallen by -$12.29 million (-55.52%). NKTR annual accounts payable is now -55.52% below its all-time high of $22.14 million, reached on 31 December 2020.NKTR Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$8.58 M
+$2.10 M+32.46%
30 September 2024
Summary:
Nektar Therapeutics quarterly accounts payable is currently $8.58 million, with the most recent change of +$2.10 million (+32.46%) on 30 September 2024. Over the past year, it has increased by +$5.29 million (+160.86%). NKTR quarterly accounts payable is now -77.85% below its all-time high of $38.72 million, reached on 30 June 2001.NKTR Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NKTR Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -24.1% | +160.9% |
| 3 y3 years | -55.5% | -63.8% |
| 5 y5 years | +68.2% | -61.0% |
NKTR Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -55.5% | +1.0% | -63.8% | +227.5% |
| 5 y | 5 years | -55.5% | +68.2% | -63.8% | +227.5% |
| alltime | all time | -55.5% | +3182.7% | -77.8% | +2759.0% |
Nektar Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $8.58 M(+32.5%) |
| June 2024 | - | $6.47 M(-26.1%) |
| Mar 2024 | - | $8.76 M(-11.1%) |
| Dec 2023 | $9.85 M(-24.1%) | $9.85 M(+199.5%) |
| Sept 2023 | - | $3.29 M(+25.5%) |
| June 2023 | - | $2.62 M(-29.1%) |
| Mar 2023 | - | $3.70 M(-71.5%) |
| Dec 2022 | $12.98 M(+33.2%) | $12.98 M(+143.6%) |
| Sept 2022 | - | $5.33 M(-56.8%) |
| June 2022 | - | $12.35 M(-2.1%) |
| Mar 2022 | - | $12.62 M(+29.4%) |
| Dec 2021 | $9.75 M(-56.0%) | $9.75 M(-58.8%) |
| Sept 2021 | - | $23.66 M(+20.1%) |
| June 2021 | - | $19.70 M(-12.2%) |
| Mar 2021 | - | $22.43 M(+1.3%) |
| Dec 2020 | $22.14 M(+15.1%) | $22.14 M(+43.0%) |
| Sept 2020 | - | $15.48 M(-19.5%) |
| June 2020 | - | $19.25 M(-11.7%) |
| Mar 2020 | - | $21.79 M(+13.3%) |
| Dec 2019 | $19.23 M(+228.6%) | $19.23 M(-12.4%) |
| Sept 2019 | - | $21.96 M(+135.0%) |
| June 2019 | - | $9.35 M(-15.1%) |
| Mar 2019 | - | $11.01 M(+88.1%) |
| Dec 2018 | $5.85 M(+22.4%) | $5.85 M(-21.9%) |
| Sept 2018 | - | $7.49 M(-29.8%) |
| June 2018 | - | $10.67 M(-6.2%) |
| Mar 2018 | - | $11.38 M(+137.9%) |
| Dec 2017 | $4.78 M(+69.8%) | $4.78 M(-44.2%) |
| Sept 2017 | - | $8.56 M(+37.2%) |
| June 2017 | - | $6.24 M(-10.2%) |
| Mar 2017 | - | $6.95 M(+146.8%) |
| Dec 2016 | $2.82 M(+19.2%) | $2.82 M(-60.4%) |
| Sept 2016 | - | $7.12 M(+205.8%) |
| June 2016 | - | $2.33 M(-0.9%) |
| Mar 2016 | - | $2.35 M(-0.6%) |
| Dec 2015 | $2.36 M(-12.6%) | $2.36 M(+3.7%) |
| Sept 2015 | - | $2.28 M(-19.6%) |
| June 2015 | - | $2.83 M(-43.6%) |
| Mar 2015 | - | $5.02 M(+85.9%) |
| Dec 2014 | $2.70 M(-70.3%) | $2.70 M(-50.2%) |
| Sept 2014 | - | $5.43 M(-27.0%) |
| June 2014 | - | $7.44 M(+142.7%) |
| Mar 2014 | - | $3.06 M(-66.4%) |
| Dec 2013 | $9.12 M(+218.4%) | $9.12 M(+144.8%) |
| Sept 2013 | - | $3.72 M(-33.2%) |
| June 2013 | - | $5.57 M(+32.1%) |
| Mar 2013 | - | $4.22 M(+47.3%) |
| Dec 2012 | $2.86 M(-5.2%) | $2.86 M(+9.1%) |
| Sept 2012 | - | $2.62 M(-15.8%) |
| June 2012 | - | $3.12 M(+77.1%) |
| Mar 2012 | - | $1.76 M(-41.7%) |
| Dec 2011 | $3.02 M(-58.0%) | $3.02 M(+38.8%) |
| Sept 2011 | - | $2.17 M(-32.9%) |
| June 2011 | - | $3.24 M(-6.8%) |
| Mar 2011 | - | $3.48 M(-51.6%) |
| Dec 2010 | $7.19 M(+134.6%) | $7.19 M(+63.4%) |
| Sept 2010 | - | $4.40 M(-4.8%) |
| June 2010 | - | $4.63 M(-18.3%) |
| Mar 2010 | - | $5.66 M(+84.7%) |
| Dec 2009 | $3.07 M | $3.07 M(-52.1%) |
| Sept 2009 | - | $6.40 M(+29.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2009 | - | $4.93 M(+84.3%) |
| Mar 2009 | - | $2.67 M(-80.7%) |
| Dec 2008 | $13.83 M(+285.4%) | $13.83 M(+554.6%) |
| Sept 2008 | - | $2.11 M(+13.5%) |
| June 2008 | - | $1.86 M(+19.7%) |
| Mar 2008 | - | $1.56 M(-56.6%) |
| Dec 2007 | $3.59 M(-56.0%) | $3.59 M(-18.8%) |
| Sept 2007 | - | $4.42 M(+50.3%) |
| June 2007 | - | $2.94 M(-19.6%) |
| Mar 2007 | - | $3.66 M(-55.2%) |
| Dec 2006 | $8.16 M(-56.8%) | $8.16 M(+20.7%) |
| Sept 2006 | - | $6.76 M(-30.8%) |
| June 2006 | - | $9.77 M(-33.2%) |
| Mar 2006 | - | $14.63 M(-22.6%) |
| Dec 2005 | $18.89 M(+164.6%) | $18.89 M(+117.0%) |
| Sept 2005 | - | $8.71 M(+2.9%) |
| June 2005 | - | $8.46 M(+65.4%) |
| Mar 2005 | - | $5.12 M(-28.3%) |
| Dec 2004 | $7.14 M(-11.6%) | $7.14 M(+51.7%) |
| Sept 2004 | - | $4.71 M(-7.1%) |
| June 2004 | - | $5.07 M(-45.9%) |
| Mar 2004 | - | $9.36 M(+16.0%) |
| Dec 2003 | $8.07 M(-6.7%) | $8.07 M(+23.8%) |
| Sept 2003 | - | $6.52 M(+33.0%) |
| June 2003 | - | $4.90 M(-25.6%) |
| Mar 2003 | - | $6.59 M(-23.8%) |
| Dec 2002 | $8.65 M(+12.6%) | $8.65 M(+66.5%) |
| Sept 2002 | - | $5.20 M(-25.0%) |
| June 2002 | - | $6.93 M(+11.7%) |
| Mar 2002 | - | $6.20 M(-19.3%) |
| Dec 2001 | $7.68 M(+18.2%) | $7.68 M(-78.7%) |
| Sept 2001 | - | $36.16 M(-6.6%) |
| June 2001 | - | $38.72 M(+36.6%) |
| Mar 2001 | - | $28.35 M(+336.1%) |
| Dec 2000 | $6.50 M(-51.4%) | $6.50 M(-62.1%) |
| Sept 2000 | - | $17.16 M(-21.6%) |
| June 2000 | - | $21.89 M(-7.8%) |
| Mar 2000 | - | $23.74 M(+77.5%) |
| Dec 1999 | $13.37 M(+263.6%) | $13.37 M(+13.2%) |
| Sept 1999 | - | $11.81 M(-5.3%) |
| June 1999 | - | $12.47 M(+14.4%) |
| Mar 1999 | - | $10.90 M(+196.4%) |
| Dec 1998 | $3.68 M(-38.4%) | $3.68 M(-30.7%) |
| Sept 1998 | - | $5.31 M(-42.1%) |
| June 1998 | - | $9.16 M(+16.0%) |
| Mar 1998 | - | $7.90 M(+32.2%) |
| Dec 1997 | $5.97 M(+443.2%) | $5.97 M(+18.6%) |
| Sept 1997 | - | $5.04 M(-2.4%) |
| June 1997 | - | $5.16 M(+72.7%) |
| Mar 1997 | - | $2.99 M(+171.5%) |
| Dec 1996 | $1.10 M(+57.1%) | $1.10 M(-26.7%) |
| Sept 1996 | - | $1.50 M(-6.3%) |
| June 1996 | - | $1.60 M(+33.3%) |
| Mar 1996 | - | $1.20 M(+71.4%) |
| Dec 1995 | $700.00 K(+133.3%) | $700.00 K(-41.7%) |
| Sept 1995 | - | $1.20 M(0.0%) |
| June 1995 | - | $1.20 M(+33.3%) |
| Mar 1995 | - | $900.00 K(+200.0%) |
| Dec 1994 | $300.00 K | $300.00 K(-80.0%) |
| Sept 1994 | - | $1.50 M(+114.3%) |
| June 1994 | - | $700.00 K(+16.7%) |
| Mar 1994 | - | $600.00 K |
FAQ
- What is Nektar Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Nektar Therapeutics?
- What is Nektar Therapeutics annual accounts payable year-on-year change?
- What is Nektar Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Nektar Therapeutics?
- What is Nektar Therapeutics quarterly accounts payable year-on-year change?
What is Nektar Therapeutics annual accounts payable?
The current annual accounts payable of NKTR is $9.85 M
What is the all time high annual accounts payable for Nektar Therapeutics?
Nektar Therapeutics all-time high annual accounts payable is $22.14 M
What is Nektar Therapeutics annual accounts payable year-on-year change?
Over the past year, NKTR annual accounts payable has changed by -$3.13 M (-24.13%)
What is Nektar Therapeutics quarterly accounts payable?
The current quarterly accounts payable of NKTR is $8.58 M
What is the all time high quarterly accounts payable for Nektar Therapeutics?
Nektar Therapeutics all-time high quarterly accounts payable is $38.72 M
What is Nektar Therapeutics quarterly accounts payable year-on-year change?
Over the past year, NKTR quarterly accounts payable has changed by +$5.29 M (+160.86%)